|
1
|
Kanda M, Shimizu D, Fujii T, Sueoka S,
Tanaka Y, Ezaka K, Takami H, Tanaka H, Hashimoto R, Iwata N, et al:
Function and diagnostic value of Anosmin-1 in gastric cancer
progression. Int J Cancer. 138:721–730. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Songun I, Putter H, Kranenbarg EM, Sasako
M and van de Velde CJ: Surgical treatment of gastric cancer:
15-year follow-up results of the randomised nationwide Dutch D1D2
trial. Lancet Oncol. 11:439–449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kanda M, Kobayashi D, Tanaka C, Iwata N,
Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Nomoto S, et
al: Adverse prognostic impact of perioperative allogeneic
transfusion on patients with stage II/III gastric cancer. Gastric
Cancer. 19:255–263. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
GASTRIC (Global Advanced/Adjuvant Stomach
Tumor Research International Collaboration) Group, ; Paoletti X,
Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P,
Sakamoto J, Sargent D, et al: Benefit of adjuvant chemotherapy for
resectable gastric cancer: A meta-analysis. JAMA. 303:1729–1737.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh
KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, et al: Asia
Pacific Working Group on Gastric Cancer: Screening for gastric
cancer in Asia: Current evidence and practice. Lancet Oncol.
9:279–287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): A phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kanda M, Oya H, Nomoto S, Takami H,
Shimizu D, Hashimoto R, Sueoka S, Kobayashi D, Tanaka C, Yamada S,
et al: Diversity of clinical implication of B-cell translocation
gene 1 expression by histopathologic and anatomic subtypes of
gastric cancer. Dig Dis Sci. 60:1256–1264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shah MA, Khanin R, Tang L, Janjigian YY,
Klimstra DS, Gerdes H and Kelsen DP: Molecular classification of
gastric cancer: A new paradigm. Clin Cancer Res. 17:2693–2701.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kanda M, Shimizu D, Tanaka H, Shibata M,
Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, Fujii T, et
al: Metastatic pathway-specific transcriptome analysis identifies
MFSD4 as a putative tumor suppressor and biomarker for hepatic
metastasis in patients with gastric cancer. Oncotarget.
7:13667–13679. 2016.PubMed/NCBI
|
|
11
|
Zhu YX, Benn S, Li ZH, Wei E, Masih-Khan
E, Trieu Y, Bali M, McGlade CJ, Claudio JO and Stewart AK: The
SH3-SAM adaptor HACS1 is up-regulated in B cell activation
signaling cascades. J Exp Med. 200:737–747. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yan Y, Zhang L, Xu T, Zhou J, Qin R, Chen
C, Zou Y, Fu D, Hu G, Chen J and Lu Y: SAMSN1 is highly expressed
and associated with a poor survival in glioblastoma multiforme.
PLoS One. 8:e819052013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Claudio JO, Zhu YX, Benn SJ, Shukla AH,
McGlade CJ, Falcioni N and Stewart AK: HACS1 encodes a novel
SH3-SAM adaptor protein differentially expressed in normal and
malignant hematopoietic cells. Oncogene. 20:5373–5377. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamada H, Yanagisawa K, Tokumaru S,
Taguchi A, Nimura Y, Osada H, Nagino M and Takahashi T: Detailed
characterization of a homozygously deleted region corresponding to
a candidate tumor suppressor locus at 21q11-21 in human lung
cancer. Genes Chromosomes Cancer. 47:810–818. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Noll JE, Hewett DR, Williams SA, Vandyke
K, Kok C, To LB and Zannettino AC: SAMSN1 is a tumor suppressor
gene in multiple myeloma. Neoplasia. 16:572–585. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kanda M, Nomoto S, Okamura Y, Nishikawa Y,
Sugimoto H, Kanazumi N, Takeda S and Nakao A: Detection of
metallothionein 1G as a methylated tumor suppressor gene in human
hepatocellular carcinoma using a novel method of double combination
array analysis. Int J Oncol. 35:477–483. 2009.PubMed/NCBI
|
|
17
|
Kanda M, Nomoto S, Okamura Y, Hayashi M,
Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S and Nakao A:
Promoter hypermethylation of fibulin 1 gene is associated with
tumor progression in hepatocellular carcinoma. Mol Carcinog.
50:571–579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanda M, Nomoto S, Oya H, Takami H,
Shimizu D, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S,
et al: The expression of melanoma-associated Antigen D2 both in
surgically resected and serum samples serves as clinically
rrelevant biomarker of gastric cancer progression. Ann Surg Oncol.
23:(Suppl 2). S214–S221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with
S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sasako M, Sakuramoto S, Katai H, Kinoshita
T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and
Ohashi Y: Five-year outcomes of a randomized phase III trial
comparing adjuvant chemotherapy with S-1 versus surgery alone in
stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Japanese Gastric Cancer Association, .
Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric
Cancer. 14:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kanda M, Sugimoto H, Nomoto S, Oya H,
Hibino S, Shimizu D, Takami H, Hashimoto R, Okamura Y, Yamada S, et
al: B-cell translocation gene 1 serves as a novel prognostic
indicator of hepatocellular carcinoma. Int J Oncol. 46:641–648.
2015.PubMed/NCBI
|
|
23
|
Sobin LH, Gospodarowicz MK and Wittekind
C: International Union Against CancerTNM Classification of
Malignant Tumors. 7th. Wiley-Blackwell; New York, NY: pp. 73–77.
2009
|
|
24
|
Kanda M, Sugimoto H, Nomoto S, Oya H,
Shimizu D, Takami H, Hashimoto R, Sonohara F, Okamura Y, Yamada S,
et al: Clinical utility of PDSS2 expression to stratify patients at
risk for recurrence of hepatocellular carcinoma. Int J Oncol.
45:2005–2012. 2014.PubMed/NCBI
|
|
25
|
Kanda M, Nomoto S, Oya H, Takami H, Hibino
S, Hishida M, Suenaga M, Yamada S, Inokawa Y, Nishikawa Y, et al:
Downregulation of DENND2D by promoter hypermethylation is
associated with early recurrence of hepatocellular carcinoma. Int J
Oncol. 44:44–52. 2014.PubMed/NCBI
|
|
26
|
Oya H, Kanda M, Sugimoto H, Shimizu D,
Takami H, Hibino S, Hashimoto R, Okamura Y, Yamada S, Fujii T, et
al: Dihydropyrimidinase-like 3 is a putative hepatocellular
carcinoma tumor suppressor. J Gastroenterol. 50:590–600. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shimizu D, Kanda M, Nomoto S, Oya H,
Takami H, Hibino S, Suenaga M, Inokawa Y, Hishida M, Takano N, et
al: Identification of intragenic methylation in the TUSC1 gene as a
novel prognostic marker of hepatocellular carcinoma. Oncol Rep.
31:1305–1313. 2014.PubMed/NCBI
|
|
28
|
Resende C, Thiel A, Machado JC and
Ristimäki A: Gastric cancer: Basic aspects. Helicobacter. 16:(Suppl
1). S38–S44. 2011. View Article : Google Scholar
|
|
29
|
Yasui W, Sentani K, Sakamoto N, Anami K,
Naito Y and Oue N: Molecular pathology of gastric cancer: Research
and practice. Pathol Res Pract. 207:608–612. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Janjigian YY and Kelsen DP: Genomic
dysregulation in gastric tumors. J Surg Oncol. 107:237–242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bird A: Perceptions of epigenetics.
Nature. 447:396–398. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jones PA: Functions of DNA methylation:
Islands, start sites, gene bodies and beyond. Nat Rev Genet.
13:484–492. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oya H, Kanda M, Takami H, Hibino S,
Shimizu D, Niwa Y, Koike M, Nomoto S, Yamada S, Nishikawa Y, et al:
Overexpression of melanoma-associated antigen D4 is an independent
prognostic factor in squamous cell carcinoma of the esophagus. Dis
Esophagus. 28:188–195. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hibino S, Kanda M, Oya H, Takami H,
Shimizu D, Nomoto S, Hishida M, Niwa Y, Koike M, Yamada S, et al:
Reduced expression of DENND2D through promoter hypermethylation is
an adverse prognostic factor in squamous cell carcinoma of the
esophagus. Oncol Rep. 31:693–700. 2014.PubMed/NCBI
|
|
35
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kanda M, Nomoto S, Oya H, Hashimoto R,
Takami H, Shimizu D, Sonohara F, Kobayashi D, Tanaka C, Yamada S,
et al: Decreased expression of prenyl diphosphate synthase subunit
2 correlates with reduced survival of patients with gastric cancer.
J Exp Clin Cancer Res. 33:882014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang D, Stewart AK, Zhuang L, Zhu Y, Wang
Y, Shi C, Keating A, Slutsky A, Zhang H and Wen XY: Enhanced
adaptive immunity in mice lacking the immunoinhibitory adaptor
Hacs1. FASEB J. 24:947–956. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lang PA, Recher M, Häussinger D and Lang
KS: Genes determining the course of virus persistence in the liver:
Lessons from murine infection with lymphocytic choriomeningitis
virus. Cell Physiol Biochem. 26:263–272. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stagg J and Galipeau J: Mechanisms of
immune modulation by mesenchymal stromal cells and clinical
translation. Curr Mol Med. 13:856–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ringelhan M, Reisinger F, Yuan D, Weber A
and Heikenwalder M: Modeling human liver cancer heterogeneity:
Virally induced transgenic models and mouse genetic models of
chronic liver inflammation. Curr Protoc Pharmacol.
67:14.31.11–14.31.17. 2014.
|
|
41
|
Dicken BJ, Bigam DL, Cass C, Mackey JR,
Joy AA and Hamilton SM: Gastric adenocarcinoma: Review and
considerations for future directions. Ann Surg. 241:27–39.
2005.PubMed/NCBI
|
